AUSTIN, Texas, March 26, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced the appointment of Ivana Magovčević-Liebisch, Ph.D., J.D., to its Board of Directors. Dr. Magovčević-Liebisch is the executive vice president, chief business officer of Ipsen, a global biopharmaceutical group focused on innovation and specialty care with medicines in oncology, neuroscience and rare diseases.
“Ivana’s breadth of experience comes from more than two decades of impressive legal, commercial, transactional and scientific work,” said Anthony G. Quinn, M.B Ch.B, Ph.D., interim chief executive officer of Aeglea. “She is a multitalented executive with particular expertise in the rare genetic disease and cancer therapeutic areas, and we are excited to have her join the Aeglea team.”
“I look forward to working with Aeglea during this important time as it advances both its lead development program, pegzilarginase, and its research pipeline of additional enzyme-based therapeutics,” said Dr. Magovčević-Liebisch.
Prior to joining Ipsen, Dr. Magovčević-Liebisch was the executive vice president, chief strategy and corporate development officer for Axcella Health Inc. Before that, she was a senior vice president and the head of global business development for Teva Pharmaceutical Industries, where she was responsible for the global transaction group supporting the company’s specialty and new therapeutic entity business, among other duties. From 2001 to 2013, Dr. Magovčević-Liebisch worked for Dyax Corp, rising to the positions of executive vice president and chief operating officer. During that time, she established the commercial infrastructure of the company’s first FDA-approved drug, Kalbitor®, for treatment of hereditary angioedema attacks. Dr. Magovčević-Liebisch is currently a member of the boards of Alivio Therapeutics and Applied Genetic Technologies Corporation. She also serves as a trustee of Suffolk University, and an overseer of the Boston Ballet, Boston Museum of Science and Beth Israel Deaconess Medical Center. Dr. Magovčević-Liebisch has a B.A. in biology and chemistry from Wheaton College, a Ph.D. in genetics from Harvard University Medical School and a J.D. High Technology law from Suffolk University Law School.
About Aeglea BioTherapeutics
Aeglea is a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. The Company is developing pegzilarginase, its lead investigational therapy, for the treatment of Arginase 1 Deficiency, as monotherapy in arginine-dependent cancers and in combination with an immune checkpoint inhibitor for small cell lung cancer. In addition, Aeglea has an active research pipeline of other human enzyme-based approaches in both therapeutic areas. For more information, please visit http://aegleabio.com.
Safe Harbor / Forward Looking Statements
This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, statements we make regarding our cash forecasts, the timing and success of our clinical trials and related data, the timing of announcements and updates relating to our clinical trials and related data, our ability to enroll patients into our clinical trials, success in our collaborations and the potential therapeutic benefits and economic value of our lead product candidate or other product candidates. Further information on potential risk factors that could affect our business and its financial results are detailed in our most recent Annual Report on Form 10-K for the year ended December 31, 2017 filed with the Securities and Exchange Commission (SEC), and other reports as filed with the SEC. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Investor Contact:
Charles N. York II
Chief Financial Officer
Aeglea BioTherapeutics
investors@aegleabio.com
Media Contact:
David Calusdian
Sharon Merrill Associates
AGLE@investorrelations.com